| Description | Ingliforib (CP 368296) is a novel glycogen phosphorylase inhibitor,has antihyperglycemic and cardioprotective properties. |
| Target activity | GP (muscle):352 nM (IC50), GP (Brain):150 nM (IC50), GP (liver):52 nM (IC50) |
| Synonyms | GPi 296, CP 368296 |
| molecular weight | 457.91 |
| Molecular formula | C23H24ClN3O5 |
| CAS | 186392-65-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 125 mg/mL(272.98 mM), Sonication is recommended. |
| References | 1. Tracey WR, et al. Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor. Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1177-84. 2. Nkansah P , Antipas A , Lu Y , et al. Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs[J]. Journal of Controlled Release, 2013, 169(1-2):150-161. |